Risk-Stratified Venous Thromboembolism Chemoprophylaxis After Total Joint Arthroplasty: Evaluation of an Institutional Approach

被引:0
作者
Hyland, Sara J. [1 ,2 ]
Fada, Maria J. [2 ]
Secic, Michelle [3 ]
Fada, Robert A. [4 ]
Lockhart, Marie M. [5 ]
Parrish, Richard H. [6 ]
机构
[1] OhioHealth, Grant Med Ctr, Dept Pharm, Columbus, OH 43215 USA
[2] Ohio Univ, Heritage Coll Osteopath Med, Athens, OH 45701 USA
[3] Sec Stat Consulting Inc, Cleveland Hts, OH 44106 USA
[4] OhioHealth Grant Med Ctr, Dept Orthoped, Columbus, OH 43215 USA
[5] OhioHealth Res Inst, Columbus, OH 43214 USA
[6] Mercer Univ, Sch Med, Columbus, GA 31901 USA
关键词
aspirin; chemoprophylaxis; postoperative complications; postoperative hemorrhage; risk stratification; total joint arthroplasty; venous thromboembolism; TOTAL HIP-ARTHROPLASTY; KNEE ARTHROPLASTY; PROPHYLAXIS; ASPIRIN; GUIDELINES; THROMBOPROPHYLAXIS; ANTICOAGULANTS; RIVAROXABAN;
D O I
10.3390/jcm14020366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: The optimal venous thromboembolism (VTE) chemoprophylaxis approach after hip or knee total joint arthroplasty (TJA) remains controversial. This study aimed to characterize antithrombotic-related complications associated with various chemoprophylaxis regimens after TJA and to assess our current institutional risk-stratified prescribing tool. Methods: This retrospective case-control study and regression analysis included elective unilateral TJA patients at a single institution between 1 July 2015 and 31 December 2021. The primary outcome was a composite of antithrombotic-related complications within 30 days of surgery, including thrombotic and hemorrhagic/wound-related adverse events. The duration of anticoagulant chemoprophylaxis prescribed prior to aspirin monotherapy (0-28 days) was compared between patients who did vs. did not experience a complication, with stratification by institutionally defined VTE risk categories (Routine, Moderate, or High Risk). The complication rate was then assessed as a function of anticoagulant duration within each risk subgroup. Results: The study included 5420 patients, with 279 (5.2%) experiencing >= 1 complication. Routine VTE risk patients experienced few complications, with no significant difference between aspirin monotherapy and various initial anticoagulant durations (p = 0.6118). Moderate and High VTE Risk patients saw significantly lower complication rates with initial anticoagulant prophylaxis of increasing durations (p = 0.0090 and p = 0.0050), with a significant overall effect of VTE Risk strata observed (p = 0.0006). Conclusions: When both bleeding and thrombotic events are considered, anticoagulant-to-aspirin regimens were associated with lower complication rates than aspirin monotherapy in higher risk patients, while routine patients saw no significant benefit over aspirin. Our risk-stratified prescribing approach should be prospectively evaluated.
引用
收藏
页数:16
相关论文
共 41 条
[1]  
Alameri MA, 2020, PHARM PRACT-GRANADA, V18, DOI [10.18549/pharmpract.2020.3.2025, 10.18549/PharmPract.2020.3.2025]
[2]   Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty [J].
Anderson, D. R. ;
Dunbar, M. ;
Murnaghan, J. ;
Kahn, S. R. ;
Gross, P. ;
Forsythe, M. ;
Pelet, S. ;
Fisher, W. ;
Belzile, E. ;
Dolan, S. ;
Crowther, M. ;
Bohm, E. ;
MacDonald, S. J. ;
Gofton, W. ;
Kim, P. ;
Zukor, D. ;
Pleasance, S. ;
Andreou, P. ;
Doucette, S. ;
Theriault, C. ;
Abianui, A. ;
Carrier, M. ;
Kovacs, M. J. ;
Rodger, M. A. ;
Coyle, D. ;
Wells, P. S. ;
Vendittoli, P. -A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :699-707
[3]   Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty A Randomized Trial [J].
Anderson, David R. ;
Dunbar, Michael J. ;
Bohm, Eric R. ;
Belzile, Etienne ;
Kahn, Susan R. ;
Zukor, David ;
Fisher, William ;
Gofton, Wade ;
Gross, Peter ;
Pelet, Stephane ;
Crowther, Mark ;
MacDonald, Steven ;
Kim, Paul ;
Pleasance, Susan ;
Davis, Nicki ;
Andreou, Pantelis ;
Wells, Philip ;
Kovacs, Michael ;
Rodger, Marc A. ;
Ramsay, Tim ;
Carrier, Marc ;
Vendittoli, Pascal-Andre .
ANNALS OF INTERNAL MEDICINE, 2013, 158 (11) :800-+
[5]   Host-related factors for venous thromboembolism following total joint replacement: A meta-analysis of 89 observational studies involving over 14 million hip and knee replacements [J].
Barrett, Matthew C. ;
Whitehouse, Michael R. ;
Blom, Ashley W. ;
Kunutsor, Setor K. .
JOURNAL OF ORTHOPAEDIC SCIENCE, 2020, 25 (02) :267-275
[6]  
Caldeira D, 2017, CLIN MED INSIGHTS-BL, V10, DOI 10.1177/1179545X17704660
[7]   A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal [J].
Chan, Noel C. ;
Siegal, Deborah ;
Lauw, Mandy N. ;
Ginsberg, Jeffrey S. ;
Eikelboom, John W. ;
Guyatt, Gordon H. ;
Hirsh, Jack .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 40 (02) :231-239
[8]  
Colleoni Jose Luiz, 2018, Rev. bras. ortop., V53, P22, DOI 10.1016/j.rboe.2017.11.007
[9]   Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Falck-Ytter, Yngve ;
Francis, Charles W. ;
Johanson, Norman A. ;
Curley, Catherine ;
Dahl, Ola E. ;
Schulman, Sam ;
Ortel, Thomas L. ;
Pauker, Stephen G. ;
Colwell, Clifford W., Jr. .
CHEST, 2012, 141 (02) :E278S-E325S
[10]   Is It Time to Comprehensively Utilize Low-Dose Aspirin for Preventing Venous Thromboembolism After Total Knee Arthroplasty?: Commentary on an article by Monish S. Lavu, MHM, et al.: "Low-Dose Aspirin Is the Safest Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty Across All Patient Risk Profiles" [J].
Fu, Shau-Huai ;
Wang, Chen-Yu .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2024, 106 (14)